vs
Side-by-side financial comparison of MFA FINANCIAL, INC. (MFA) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $55.5M, roughly 1.4× MFA FINANCIAL, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 9.2%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.7%).
MFA Financial, Inc. is a U.S.-headquartered real estate investment trust (REIT) specializing in investing in and managing residential and commercial mortgage-backed securities, mortgage loans, and other real estate-related financial assets. It caters primarily to institutional and individual investors across the U.S., focusing on delivering stable risk-adjusted returns via rigorous asset screening and risk management frameworks.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
MFA vs PBYI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.5M | $75.5M |
| Net Profit | — | — |
| Gross Margin | — | 69.3% |
| Operating Margin | 97.9% | 22.7% |
| Net Margin | — | — |
| Revenue YoY | 9.2% | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.43 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.5M | $75.5M | ||
| Q3 25 | $56.8M | $54.5M | ||
| Q2 25 | $61.3M | $52.4M | ||
| Q1 25 | $57.5M | $46.0M | ||
| Q4 24 | $50.8M | $59.1M | ||
| Q3 24 | $50.6M | $80.5M | ||
| Q2 24 | $53.5M | $47.1M | ||
| Q1 24 | $47.8M | $43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $48.1M | $8.8M | ||
| Q2 25 | $33.2M | $5.9M | ||
| Q1 25 | $41.2M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.2M | $20.3M | ||
| Q2 24 | $41.9M | $-4.5M | ||
| Q1 24 | $23.2M | $-4.8M |
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
| Q4 25 | 97.9% | 22.7% | ||
| Q3 25 | 84.5% | 17.6% | ||
| Q2 25 | 54.5% | 12.7% | ||
| Q1 25 | 70.0% | 8.7% | ||
| Q4 24 | 6.8% | 22.6% | ||
| Q3 24 | 98.2% | 27.4% | ||
| Q2 24 | 79.1% | -4.6% | ||
| Q1 24 | 50.7% | -5.3% |
| Q4 25 | — | — | ||
| Q3 25 | 84.7% | 16.2% | ||
| Q2 25 | 54.2% | 11.2% | ||
| Q1 25 | 71.6% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 95.2% | 25.2% | ||
| Q2 24 | 78.4% | -9.6% | ||
| Q1 24 | 48.5% | -11.0% |
| Q4 25 | $0.43 | $0.26 | ||
| Q3 25 | $0.35 | $0.17 | ||
| Q2 25 | $0.21 | $0.12 | ||
| Q1 25 | $0.31 | $0.06 | ||
| Q4 24 | $-0.01 | $0.40 | ||
| Q3 24 | $0.37 | $0.41 | ||
| Q2 24 | $0.32 | $-0.09 | ||
| Q1 24 | $0.14 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.2M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | $1.8B | $130.3M |
| Total Assets | $13.0B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.2M | $97.5M | ||
| Q3 25 | $305.2M | $94.4M | ||
| Q2 25 | $275.7M | $96.0M | ||
| Q1 25 | $253.7M | $93.2M | ||
| Q4 24 | $338.9M | $101.0M | ||
| Q3 24 | $305.6M | $96.7M | ||
| Q2 24 | $289.4M | $96.8M | ||
| Q1 24 | $306.3M | $107.2M |
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
| Q4 25 | $1.8B | $130.3M | ||
| Q3 25 | $1.8B | $115.3M | ||
| Q2 25 | $1.8B | $104.7M | ||
| Q1 25 | $1.8B | $97.1M | ||
| Q4 24 | $1.8B | $92.1M | ||
| Q3 24 | $1.9B | $71.1M | ||
| Q2 24 | $1.9B | $48.5M | ||
| Q1 24 | $1.9B | $51.0M |
| Q4 25 | $13.0B | $216.3M | ||
| Q3 25 | $12.1B | $202.9M | ||
| Q2 25 | $11.7B | $194.9M | ||
| Q1 25 | $11.5B | $196.2M | ||
| Q4 24 | $11.4B | $213.3M | ||
| Q3 24 | $11.2B | $220.7M | ||
| Q2 24 | $11.1B | $205.0M | ||
| Q1 24 | $10.9B | $214.1M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $76.2M | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.2M | $14.4M | ||
| Q3 25 | $14.7M | $9.7M | ||
| Q2 25 | $38.5M | $14.1M | ||
| Q1 25 | $-14.6M | $3.6M | ||
| Q4 24 | $200.1M | $15.6M | ||
| Q3 24 | $-11.3M | $11.0M | ||
| Q2 24 | $46.5M | $1.0M | ||
| Q1 24 | $53.5M | $11.2M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.31× | 1.10× | ||
| Q2 25 | 1.16× | 2.41× | ||
| Q1 25 | -0.35× | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.23× | 0.54× | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 2.30× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
